Your browser is no longer supported. Please, upgrade your browser.
BridgeBio Pharma, Inc.
Index- P/E- EPS (ttm)-3.90 Insider Own3.40% Shs Outstand146.66M Perf Week-11.90%
Market Cap6.13B Forward P/E- EPS next Y-3.81 Insider Trans-0.26% Shs Float97.54M Perf Month-19.17%
Income-535.30M PEG- EPS next Q-0.78 Inst Own93.60% Short Float12.00% Perf Quarter-21.65%
Sales57.00M P/S107.49 EPS this Y-53.40% Inst Trans-4.16% Short Ratio14.57 Perf Half Y-33.19%
Book/sh-5.07 P/B- EPS next Y3.20% ROA-58.50% Target Price81.20 Perf Year-18.40%
Cash/sh3.87 P/C10.22 EPS next 5Y- ROE138.60% 52W Range37.94 - 73.50 Perf YTD-44.38%
Dividend- P/FCF- EPS past 5Y- ROI-88.40% 52W High-47.07% Beta-
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin97.30% 52W Low2.53% ATR2.04
Employees385 Current Ratio6.70 Sales Q/Q-71.60% Oper. Margin- RSI (14)25.58 Volatility5.89% 4.50%
OptionableYes Debt/Eq- EPS Q/Q-8.40% Profit Margin- Rel Volume0.46 Prev Close39.55
ShortableYes LT Debt/Eq- EarningsNov 04 BMO Payout- Avg Volume803.66K Price38.90
Recom1.80 SMA20-17.74% SMA50-18.46% SMA200-29.78% Volume152,308 Change-1.64%
Sep-10-21Upgrade BofA Securities Neutral → Buy $75
May-21-21Initiated UBS Buy $80
Mar-22-21Reiterated Goldman Buy $83 → $91
Feb-22-21Resumed JP Morgan Overweight $78
Feb-09-21Resumed Goldman Buy $83
Jan-11-21Reiterated H.C. Wainwright Buy $64 → $87
Dec-10-20Reiterated H.C. Wainwright Buy $53 → $64
Jun-25-20Initiated BofA/Merrill Neutral $38
May-19-20Initiated BTIG Research Buy $49
Apr-13-20Initiated H.C. Wainwright Buy $50
Feb-19-20Initiated Mizuho Buy $51
Jul-26-19Initiated Raymond James Outperform $36
Jul-22-19Initiated SVB Leerink Outperform $34
Jul-22-19Initiated Piper Jaffray Overweight $50
Jul-22-19Initiated JP Morgan Overweight $38
Jul-22-19Initiated Jefferies Buy $38
Jul-22-19Initiated Goldman Buy $42
Jul-22-19Initiated BMO Capital Markets Outperform $49
Nov-29-21 07:36AM  
Nov-24-21 08:32AM  
Nov-19-21 07:30AM  
Nov-18-21 01:21PM  
Nov-04-21 09:25AM  
Nov-03-21 07:30AM  
Oct-29-21 07:30AM  
Oct-25-21 07:30AM  
Oct-18-21 05:19AM  
Oct-12-21 07:30AM  
Oct-07-21 09:00AM  
Oct-06-21 07:30AM  
Oct-01-21 05:57PM  
Sep-15-21 08:47AM  
Sep-08-21 05:00PM  
Aug-30-21 01:36AM  
Aug-25-21 07:00AM  
Aug-23-21 10:01AM  
Aug-18-21 02:22PM  
Aug-07-21 03:07AM  
Aug-05-21 09:05AM  
Aug-04-21 07:01PM  
Jul-27-21 07:30AM  
Jul-13-21 10:42AM  
Jul-12-21 04:30PM  
Jul-08-21 07:30AM  
Jul-01-21 02:15PM  
Jun-28-21 07:10PM  
Jun-19-21 07:00AM  
Jun-14-21 04:35PM  
Jun-05-21 06:31AM  
Jun-02-21 05:44PM  
Jun-01-21 08:02AM  
May-28-21 02:30PM  
May-14-21 04:30PM  
May-06-21 09:15AM  
May-03-21 08:15AM  
Apr-30-21 01:39PM  
Apr-24-21 12:40PM  
Apr-13-21 07:45AM  
Apr-06-21 04:30PM  
Mar-31-21 11:46AM  
Mar-20-21 11:00AM  
Mar-16-21 01:20PM  
Mar-02-21 04:30PM  
Mar-01-21 09:56AM  
Feb-28-21 08:00AM  
Feb-26-21 08:46AM  
Feb-25-21 07:30AM  
Feb-24-21 04:01PM  
Feb-19-21 01:01PM  
Feb-17-21 12:49PM  
Feb-12-21 08:00AM  
Feb-11-21 04:09PM  
Feb-05-21 04:30PM  
Feb-02-21 07:30AM  
Jan-26-21 08:30AM  
Jan-25-21 11:04PM  
Jan-19-21 04:01PM  
Jan-13-21 04:30PM  
Jan-08-21 06:56AM  
Jan-06-21 04:30PM  
Jan-05-21 06:23AM  
Jan-04-21 11:42AM  
Dec-26-20 10:05AM  
Dec-23-20 07:30AM  
Dec-19-20 04:11PM  
Dec-17-20 11:08PM  
Dec-14-20 08:43PM  
Dec-11-20 09:13PM  
Dec-07-20 08:30AM  
Dec-04-20 04:30PM  
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); the University of California; and Helsinn Group, as well as a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398. The company was founded in 2015 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHELLER RICHARD HSee RemarksAug 04Option Exercise17.0013,777234,20959,637Aug 06 06:08 PM
SCHELLER RICHARD HSee RemarksAug 04Sale53.2313,777733,31745,860Aug 06 06:08 PM
Scott Randal W.DirectorFeb 17Buy62.5016,0001,000,00021,000Feb 18 06:21 PM
STEPHENSON BRIAN CSee RemarksFeb 17Buy62.508,000500,000300,043Feb 18 08:33 PM
KKR Genetic Disorder L.P.10% OwnerFeb 17Sale60.473,450,000208,617,36031,060,971Feb 17 05:36 PM
Turtle CameronSee RemarksDec 28Option Exercise6.6919,500130,50032,068Dec 29 09:14 PM
Turtle CameronSee RemarksDec 28Sale69.6019,5001,357,18412,568Dec 29 09:14 PM
SCHELLER RICHARD HSee RemarksDec 21Sale65.3260,4013,945,13745,860Dec 23 05:35 PM
SCHELLER RICHARD HSee RemarksDec 18Sale65.0730,0001,952,021106,261Dec 21 04:05 PM
SCHELLER RICHARD HSee RemarksDec 15Option Exercise17.0029,277497,709167,704Dec 17 04:05 PM
SCHELLER RICHARD HSee RemarksDec 15Sale60.3831,4431,898,417136,261Dec 17 04:05 PM
HENDERSON MICHAEL THOMASChief Business OfficerDec 01Option Exercise1.0510,00010,500284,211Dec 02 04:17 PM
HENDERSON MICHAEL THOMASChief Business OfficerDec 01Sale51.5210,000515,204274,211Dec 02 04:17 PM